Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses

Immunological Reviews

Volumn 159, Issue , 1997, Pages 17-29

  Goulder, Philip ^a   Price, David ^a   Nowak, Martin ^b   Rowland Jones, Sarah ^a   Phillips, Rodney ^a   McMichael, Andrew ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS CELL INTERACTION;

EID: 0030665003     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb01004.x     Document Type: Review

References (91)

1. Koup RA, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
2. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
3. Yang OO, et al. Efficient lysis of HIV-1 infected cells by cytotoxic T lymphocytes. J Virol 1996;70:5799-5806.
4. Klenerman P, et al. Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. Proc Natl Acad Sci USA 1996;271:497-499.
5. Pantaleo G, et al. Major expansion of CD8+ T cells with a predominant Vb usage during the primary immune response to HIV. Nature 1994;370:463-467.
6. Borrow P, et al. Antiviral pressure exerted by HIV-1 specific CTL during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-211.
7. Gotch FM, Nixon DF, Alp N, McMichael AJ, Borysiewicz LK. High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int Immunol 1990;2:707-712.
8. Moss PAH, et al. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc Natl Acad Sci USA 1995;92:5773-5777.
9. Altman J, et al. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. Science 1996;274:94-96.
10. Callan MFC, et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med 1996;2:906-911.
11. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993;177:249-256.
12. Rinaldo C, et al. High levels of anti-human immunodeficiency virus type 1 memory cytotoxic T lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long term non-progressors. J Virol 1995;69:5838-5842.
13. Klein MR, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-1372.
14. Goulder PJR, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-217.
15. Margolick JB, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. Nat Med 1995;7:674-680.
16. Jurriaans S, et al. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994;204:223-233.
17. Henrard DR, et al. Natural history of HIV-1 cell-free viraemia. JAMA 1995;274:554-558.
18. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
19. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996;347:1573-1579.
20. Pantaleo G, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997;94:254-258.
21. Bevan MJ, Braciale TJ. Why can't cytotoxic T cells handle HIV? Proc Natl Acad Sci USA 1995;92:5765-5767.
22. Feinberg MB, McLean AR. AIDS: Decline and fall of immune surveillance? Curr Biol 1997;7:136-140.
23. Johnson RP, et al. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol 1991;147:1512-1521.
24. Koenig S, et al. Transfer of HIV-1 specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995;1:330-336.
25. Mathieson BJ. CTL to HIV-1: surrogates or sirens. Nat Med 1995;1:304-305.
26. Phillips AN. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science 1996;271:497-499.
27. Pantaleo G, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-358.
28. Embretson J, et al. Massive covert infection of helper T lymphocytres and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-362.
29. Barre-Sinoussi F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk of acquired immune deficiency syndrome (AIDS). Science 1983;220:868-871.
30. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995;69:5087-5094.
31. Holland JJ, Spindler K, Horodyski F, Grabau E, Nichol S, VandePol S. Rapid evolution of RNA genomes. Science 1982;215:1577-1588.
32. Steinhauer DA, Holland JJ. Rapid evolution of RNA viruses. Annu Rev Microbiol 1987;41:409-433.
33. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321:1621-1625.
34. Wei X, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
35. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
36. Wain-Hobson S. Virological mayhem. Nature 1995;373:102.
37. Cheynier R, et al. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell 1994;78:373-387.
38. McCune JM. HIV-1: the infective process in vivo. Cell 1991;64:351-363.
39. Pircher H, Moskphidis A, Rohrer U, Burki K, Hengartner H, Zinkernagel RM. Viral escape by selection of cytotoxic T cell-resistant variants in vivo. Nature 1990;346:629-633.
40. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee H-G. Allele specific motifs revealed by sequencing of self peptides eluted from MHC molecules. Nature 1991;351:290-296.
41. b at 2.4A resolution. Cell 1994;76:39-50.
42. Lewicki H, et al. CTL escape variants. I. Generation and Molecular Characterization. Virology 1995;210:29-40.
43. Moskophidis D, Zinkernagel RM. Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus. J Virol 1995;69:2187-2193.
44. Lewicki HA, Von Herrath MG, Evans CF, Whitton JL, Oldstone MBA. CTL escape viral variants. II Biologic activity in vivo. Virology 1995;211:443-450.
45. Moskophidis D, Zinkernagel RM. Immunobiology of cytotoxic T-cell resistant virus variants: studies on lymphocytic choriomeningitis virus. Semin Virol 1996;7:3-11.
46. Pewe L, Wu GF, Barnett EM, Castro RF, Perlman S. Cytotoxic T cell-resistant variants are selected in a virus-induced demyelinating disease. Immunity 1996;5:253-262.
47. Green WR, Smith PM. Endogenous ecotropic and recominant MCF mouse retroviral variation and escape from antiviral CTL. Semin Virol 1996;7:49-60.
48. Sijts AJAM, Ossendorp F, Mengede EA, van den Elsen PJ, Melief CJM. Immunodominant mink cell focus-inducing murine leukaemia virus (MuLV)- encoded CTL epitope, identified by its MHC class I binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes. J Immunol 1994;152:106-116.
49. Ossendorp F, et al. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in a lack of antigen presentation. Immunity 1996;5:115-124.
50. McMichael AJ. How viruses hide from T cells. Trends Microbiol 1997 (In press).
51. Phillips RE, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991;354:453-459.
52. Steel CM, et al. HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet 1988;1:1185-1188.
53. Kaslow RA, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996;2:404-411.
54. Nowak MA, et al. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995;375:606-611.
55. Goulder PJR, et al. Patterns of immunodominance in HIV-1 specific cytotoxic T lymphocyte responses in two HLA-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med 1997;185:1423-1433.
56. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993;75:693-708.
57. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-937.
58. Couillin I, et al. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein. J Exp Med 1994;180:1129-1134.
59. Haas G, et al. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. J Immunol 1996;157:4212-4221.
60. Meyerhans A, et al. In vivo persistence of a HIV-1-encoded HLA-B27-restricted cytotoxic T lymphocyte epitope despite specific in vitro reactivity. Eur J Immunol 1991;21:2637-2640.
61. Harrer T, et al. Cytotoxic T lymphocytes in asymptomatic long-term non-progressing HIV-1 infection. J Immunol 1996;156:2616-2623.
62. Nietfield W, et al. Sequence constraints and recognition by CTL of an HLA-B27-restricted HIV-1 gag epitope. J Immunol 1995;154:2189-2197.
63. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to Zidovudine (AZT). Science 1989;246:1155-1158.
64. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
65. Price DA, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997;94:1890-1895.
66. Goulder PJR, et al. Combined structural and immunological refinement of HLA-B*8-restricted CTL epitopes. Eur J Immunol 1997 (In press).
67. Moore JP, Cao Y, Ho DD, Koup RA. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994;68:5142-5155.
68. Paul WE. Reexamining AIDS research priorities. Science 1995;267:633-636.
69. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-1566.
70. Cocchi F, DeVico AL, Garzino DA, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
71. Mackewicz CE, Ortega HW, Levy JA. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991;87:1462-1466.
72. Paxton WA, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nat Med 1996;2:412-417.
73. Dragic T, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
74. Deng H, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666.
75. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDMA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996;272:872-877.
76. Myers G, et al. eds. Human Retroviruses and AIDS. Los Alamos: Los Alamos National Laboratory; 1995.
77. Nixon DF, Townsend ARM, Elvin JG, Rizza CR, Gallwey J, McMichael AJ. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 1988;336:484-487.
78. Walker BD, et al. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989;86:9514-9518.
79. Koup RA, et al. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities. J Exp Med 1991;174:1593-1600.
80. Riviere Y, et al. Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env products. J Virol 1989;63:2270-2277.
81. McAdam S, et al. Cross clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. AIDS 1997 (Submitted).
82. Pikora CA, Sullivan JL, Panicali D, Luzuriaga K. Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected infants. J Exp Med 1997;185:1153-1161.
83. Yamaguchi Y, Gojobori T. Evolutionary mechanisms and population dynamics of the third variable envelope region of HIV within single hosts. Proc Natl Acad Sci USA 1997;94:1264-1269.
84. Wu TT, Kabat EA. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med 1970;312:211-250.
85. Nei M, Gojobori T. Simple methods for estimating the numbers of synonymous and non-synonymous nucleotide substitutions. Mol Biol Evol 1986;3:418-426.
86. Harrer T, et al. Strong cytotoxic T cells and weak neutralising antibodies in long-term non-progressing HIV-1 infection. AIDS Res Hum Retroviruses 1996;17: 585-592.
87. Wolinsky SM, et al. Adaptive evolution of Human Immunodeficiency Virus-Type 1 during the natural course of Infection. Science 1996;272:537-540.
88. Reid SW, et al. Antagonistic HIV-1 gag peptides induce structural changes in HLA-B8. J Exp Med 1996;184:2279-2286.
89. Klenerman P, et al. Naturally ocurring HIV-1 gag variants antagonise cytotoxic T-cell activity. Nature 1994;369:403-406.
90. Volberding PA, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 count of 500 or more per cubic millimetre. N Engl J Med 1993;329:401-407.
91. Concorde Coordinating Committee. MRC/ANRS randomised double-blind controlled trial in immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-881.